Polaryx Therapeutics, Inc. Common Stock (PLYX) Stock Price

PLYXStock
$1.88
Market Cap$89.01M
P/E—
PEG Ratio—
Div yield—
Beta-1.38

PLYX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-80.85%
Price vs S&P 500 (4W)-10.82%
VGM Score42.38

PLYX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.04-$0.03+25.00%(+$0.01)
Q1 2026-$0.02-$0.05-150.00%(-$0.03)
Q4 2025-$0.02-$0.16-700.00%(-$0.14)

PLYX Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.11
4.20

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
PLYXPolaryx Therapeutics, Inc. Common Stock
——C————$1.88
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics is a clinical-stage biotech company developing oral small molecule therapies for rare pediatric lysosomal storage diseases (LSDs). Its pipeline includes PLX-200, PLX-300, and PLX-100, designed to address the underlying pathophysiology of these genetic disorders. The company focuses on disease-modifying treatments that target core mechanisms common to multiple LSDs.